HLA-DR genotype risks in seropositive rheumatoid arthritis

Area of Science:

• Immunogenetics
• Rheumatology
• Human Leukocyte Antigen (HLA) complex

Background:

• Rheumatoid arthritis (RA) is an autoimmune disease with a known genetic component.
• Human Leukocyte Antigen (HLA) genes are crucial for immune response and have been implicated in autoimmune diseases.
• Previous studies suggest an association between specific HLA antigens and RA susceptibility.

Purpose of the Study:

• To investigate the distribution of HLA-A, B, C, and -DR antigens in Caucasian RA patients.
• To determine the association of specific HLA-DR genotypes with RA risk and disease characteristics.
• To explore the relationship between HLA antigens and toxic complications from gold salt treatment.

Main Methods:

• Genotyping of HLA-A, B, C, and -DR antigens in 77 Caucasian sero-positive RA patients.
• Comparison of patient genotypes with a control panel of 110 unrelated Caucasian donors.
• Statistical analysis to assess antigen frequencies, genotype risks, and associations with disease onset and treatment complications.

Main Results:

• Confirms the association of HLA-DR4 with RA.
• Identifies increased disease risk for patients carrying HLA-DR1, -DR2, and -DR3.
• Reveals a higher risk for DR4/4 homozygotes compared to heterozygotes (DR4/1, DR4/2, DR4/3).
• Suggests DR4 is more frequent in early-onset RA (before age 35).
• Shows a significant excess of HLA-DR3 in patients experiencing toxic reactions to gold salts.

Conclusions:

• Specific HLA-DR genotypes significantly influence rheumatoid arthritis susceptibility and risk.
• The observed genotype risks support the inheritance of a single, linked genetic determinant for RA.
• HLA-DR3 positivity is a potential marker for adverse reactions to gold salt therapy in RA patients.